Casak, S. J. et al. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. oncologist 16, 97–104 (2011).
Google Scholar
Chan, H. T. C. et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 63, 5480–5489 (2003).
Google Scholar
Alduaij, W. et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117, 4519–4529 (2011).
Google Scholar
van der Kolk, L. E., de Haas, M., Grillo-López, A. J., Baars, J. W. & van Oers, M. H. J. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 16, 693–699 (2002).
Google Scholar
Dall’Ozzo, S. et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64, 4664–4669 (2004).
Google Scholar
Dale, D. C., Boxer, L., Conrad & Liles, W. The phagocytes: neutrophils and monocytes. Blood 112, 935–945 (2008).
Google Scholar
Podack, E. R., Tschoop, J. & Müller-Eberhard, H. J. Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J. Exp. Med. 156, 268–282 (1982).
Google Scholar
Tschopp, J. Ultrastructure of the membrane attack complex of complement. Heterogeneity of the complex caused by different degree of C9 polymerization. J. Biol. Chem. 259, 7857–7863 (1984).
Google Scholar
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
Google Scholar
Moran, A. E., Kovacsovics-Bankowski, M. & Weinberg, A. D. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. 25, 230–237 (2013).
Google Scholar
Lohmueller J., Finn O. J. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Elsevier Inc.; p. 31–47, 2017.
Hafeez U., Gan H. K., Scott A. M. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Elsevier Ltd, p. 114–121, 2018.
Smith, R. I. F. & Morrison, S. L. Recombinant polymeric IgG: an approach to engineering more potent antibodies. Biotechnology 12, 683–688 (1994).
Google Scholar
Smith, R. I., Coloma, M. J. & Morrison, S. L. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J. Immunol. 154, 2226–2236 (1995).
Google Scholar
Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260–1263 (2014).
Google Scholar
de Jong, R. N. et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 14, e1002344-e (2016).
Google Scholar
Putnam, F. W., Florent, G., Paul, C., Shinoda, T., & Shimizu, A. Complete amino acid sequence of the Mu heavy chain of a human IgM immunoglobulin. Science 182, 287–291 (1973).
Google Scholar
Kehry, M., Sibley, C., Fuhrman, J., Schilling, J. & Hood, L. E. Amino acid sequence of a mouse immunoglobulin μ chain. Proc. Natl Acad. Sci. USA 76, 2932–2936 (1979).
Google Scholar
Davis, A. C., Roux, K. H., Pursey, J. & Shulman, M. J. Intermolecular disulfide bonding in IgM: effects of replacing cysteine residues in the mu heavy chain. EMBO J. 8, 2519–2526 (1989).
Google Scholar
Li, Y. et al. Structural insights into immunoglobulin M. Science 367, 1014–1017 (2020).
Google Scholar
Strasser, J. et al. Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces. Nano Lett. 19, 4787–4796 (2019).
Google Scholar
Kishore, U. et al. Structural and functional anatomy of the globular domain of complement protein C1q. Immunol. Lett. 95, 113–128 (2004).
Google Scholar
Sharp, T. H. et al. Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b. Proc. Natl. Acad. Sci. USA 116, 11900–11905 (2019).
Google Scholar
Ugurlar, D. et al. Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. Science 359, 794–797 (2018).
Google Scholar
Idusogie, E. E. et al. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166, 2571–2575 (2001).
Google Scholar
Lee, C.-H. et al. IgG Fc domains that bind C1q but not effector Fcgamma receptors delineate the importance of complement-mediated effector functions. Nat. Immunol. 18, 889–898 (2017).
Google Scholar
Natsume, A. et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68, 3863–3872 (2008).
Google Scholar
Saphire, E. O., Parren, P. W. H. I., Barbas, C. F., Burton, D. R. & Wilson, I. A. Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: An antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallogr. Sect. D: Biol. Crystallogr. 57, 168–171 (2001).
Google Scholar
Rowley T. F. et al. Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions. Commun. Biol. 1, 146 (2018).
Cragg, M. S. et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101, 1045–1052 (2003).
Google Scholar
Idusogie, E. E. et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164, 4178–4184 (2000).
Google Scholar
Patel, R., Neill, A., Liu, H. & Andrien, B. IgG subclass specificity to C1q determined by surface plasmon resonance using Protein L capture technique. Anal. Biochem. 479, 15–17 (2015).
Google Scholar
Deans, J. P., Robbins, S. M., Polyak, M. J. & Savage, J. A. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J. Biol. Chem. 273, 344–348 (1998).
Google Scholar
Mössner, E. et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell—mediated B-cell cytotoxicity. Blood 115, 4393–4402 (2010).
Google Scholar
Dahal, L. N. et al. Shaving is an epiphenomenon of type I and II anti-CD20–mediated phagocytosis, whereas antigenic modulation limits type I monoclonal antibody efficacy. J. Immunol. 201, 1211–1221 (2018).
Google Scholar
Tutt, A. L. et al. Development and characterization of monoclonal antibodies specific for mouse and human Fc receptors. J. Immunol. 195, 5503–5516 (2015).
Google Scholar
Ivanov, A. et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Investig. 119, 2143–2159 (2009).
Google Scholar
Chowdhury, F., Lode, H. N., Cragg, M. S., Glennie, M. J. & Gray, J. C. Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood. Cancer Immunol. Immunother. 63, 559–569 (2014).
Google Scholar
Koene, H. R. et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90, 1109–1114 (1997).
Google Scholar
Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99, 754–758 (2002).
Google Scholar
Beers, S. A. et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112, 4170–4177 (2008).
Google Scholar
Teeling, J. L. et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177, 362–371 (2006).
Google Scholar
Du, J., Yang, H., Guo, Y. & Ding, J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol. Immunol. 46, 2419–CD23 (2009).
Google Scholar
Lin, T. S. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmacogenomics Pers. Med. 3, 51–59 (2010).
Google Scholar
Barth, M. J., Mavis, C., Czuczman, M. S. & Hernandez-Ilizaliturri, F. J. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma. Clin. Cancer Res. 21, 4391–4397 (2015).
Google Scholar
Czuczman, M. S. et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 119, 3698–3704 (2012).
Google Scholar
Gulati, S. et al. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLOS Biol. 17, e3000323-e (2019).
Google Scholar
Oyong D. A., et al. Induction and kinetics of complement-fixing antibodies against Plasmodium vivax MSP3α and relationship with IgG subclasses and IgM. J. Infect. Dis. 220, 1950–1961 (2019).
Moore, G. L., Chen, H., Karki, S. & Lazar, G. A. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2, 181–189 (2010).
Google Scholar
Wang G. et al. Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen. Mol. Cell 63, 135–145 (2016).
Tammen A. et al. Monoclonal antibodies against epidermal growth factor receptor acquire an ability to kill tumor cells through complement activation by mutations that selectively facilitate the hexamerization of IgG on opsonized cells. J. Immunol. 198, 1585–1594 (2017).
Oostindie S. C. et al. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. Haematologica. 104, 1841–1852 (2018).
Pasalic, D. et al. A peptide extension dictates IgM assembly. Proc. Natl. Acad. Sci. USA 114, E8575–E8584 (2017).
Google Scholar
Mamidi, S., Cinci, M., Hasmann, M., Fehring, V. & Kirschfink, M. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol. Oncol. 7, 580–594 (2013).
Google Scholar
Walshe, C. A. et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J. Biol. Chem. 283, 16971–16984 (2008).
Google Scholar
Janas, E., Priest, R., Wilde, J. I., White, J. H. & Malhotra, R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. 139, 439–446 (2005).
Google Scholar
Cragg M. S. CD20 antibodies: doing the time warp. Am. Soc. Hematol. 118, 219–220 (2011).
Rougé, L. et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science 367, 1224–1230 (2020).
Google Scholar
Shields, R. L. et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276, 6591–6604 (2001).
Google Scholar
Radaev, S., Motyka, S., Fridman, W. H., Sautes-Fridman, C. & Sun, P. D. The structure of a human type III Fcγ receptor in complex with Fc. J. Biol. Chem. 276, 16469–16477 (2001).
Google Scholar
Ramsland, P. A. et al. Structural basis for FcγRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 187, 3208–3217 (2011).
Google Scholar
Lu, J. & Sun, P. D. Structural mechanism of high affinity FcγRI recognition of immunoglobulin G. Immunol. Rev. 268, 192–200 (2015).
Google Scholar
Johansson, A. G., Lövdal, T., Magnusson, K., Berg, T. & Skogh, T. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology 24, 169–175 (1996).
Google Scholar
Løvdal, T., Andersen, E., Brech, A. & Berg, T. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J. Cell Sci. 113, 3255–3266 (2000).
Google Scholar
Qureshi, O. S. et al. Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions. Sci. Rep. 7, 17049- (2017).
Google Scholar
Wang, S. Y., Racila, E., Taylor, R. P. & Weiner, G. J. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111, 1456–1463 (2008).
Google Scholar
Fischer, M. B., Ma, M., Hsu, N. C. & Carroll, M. C. Local synthesis of C3 within the splenic lymphoid compartment can reconstitute the impaired immune response in C3-deficient mice. J. Immunol. 160, 2619–2625 (1998).
Google Scholar
Zwirner, J., Felber, E., Schmidt, P., Riethmuller, G. & Feucht, H. E. Complement activation in human lymphoid germinal centres. Immunology 66, 270–277 (1989).
Google Scholar
Arce Vargas, F. et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46, 577–586 (2017).
Google Scholar
Cook E. M. et al. Antibodies That efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions. J. Immunol. 197, 1762–1775 (2016).
Beers, S. A. et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115, 5191–5201 (2010).
Google Scholar
Cain, K. et al. A CHO cell line engineered to express XBP1 and ERO1-α has increased levels of transient protein expression. Biotechnol. Prog. 29, 697–706 (2013).
Google Scholar
Dahal, L. N. et al. STING activation reverses lymphoma-mediated resistance to antibody immunotherapy. Cancer Res. 77, 3619–3631 (2017).
Google Scholar
